In short
This article discusses clinical trials involving the use of Dermatophagoides Pteronyssinus (503), a house dust mite allergen extract, in allergy testing and treatment. These trials aim to assess the effectiveness and safety of various immunotherapy approaches for patients with allergies to common allergens like birch pollen and grass pollen. The studies focus on sublingual immunotherapy and skin prick tests to evaluate allergic responses and potential treatments.
At a glance
- Study Type
- Phase II-III clinical trials
- Main Focus
- Efficacy and safety of sublingual immunotherapy for birch and grass pollen allergies
- Use of Dermatophagoides Pteronyssinus (503)
- Used in skin prick tests for allergy diagnosis and participant screening
- Key Inclusion Criteria
- Adults 18-65 with moderate-to-severe allergic rhinitis/rhinoconjunctivitis, positive skin prick test, specific IgE levels ≥ 0.7 kU/L
- Primary Endpoint
- Differences in Combined Symptom and Medication Score (CSMS) during peak pollen periods
- Secondary Endpoints
- Quality of life changes, symptom-free days, nasal provocation test results, safety assessments
- Treatment Duration
- Not specified in the provided information
- Safety Considerations
- Exclusion of patients with severe asthma, immune system disorders, or previous serious reactions to immunotherapy
What is DERMATOPHAGOIDES PTERONYSSINUS (503)?
DERMATOPHAGOIDES PTERONYSSINUS (503) is a medical substance derived from house dust mites. Specifically, it is an extract from the species Dermatophagoides pteronyssinus, which is one of the most common house dust mites found in homes worldwide. This substance is also known by its synonym "503 House Dust Mite Dermatophagoides pteronyssinus".
Medical Uses
DERMATOPHAGOIDES PTERONYSSINUS (503) is primarily used in the diagnosis and treatment of allergies related to house dust mites. It serves two main purposes:
- Diagnostic Tool: It is used in skin prick tests to diagnose allergies to house dust mites. These tests help doctors determine if a patient is sensitized to this specific allergen.
- Immunotherapy: While not explicitly stated in the provided clinical trial information, allergen extracts like this are often used in immunotherapy treatments to help patients build tolerance to specific allergens over time.
How is it Administered?
DERMATOPHAGOIDES PTERONYSSINUS (503) is administered as a solution for skin-prick tests. The medication is applied topically, typically in the form of drops on the skin. The maximum daily dose and total dose amount is 1 drop, and the treatment period is typically very short (around 1 time unit, likely referring to a single application).
Current Clinical Trials
While the provided clinical trial information doesn't directly focus on DERMATOPHAGOIDES PTERONYSSINUS (503), it is mentioned as part of ongoing studies related to allergies. These studies are investigating treatments for other common allergens like birch pollen and grass pollen. This suggests that DERMATOPHAGOIDES PTERONYSSINUS (503) may be used as a comparative or control substance in these trials, or to screen participants for additional allergies.
Patient Eligibility for Clinical Trials
While the specific trials mentioned do not focus on DERMATOPHAGOIDES PTERONYSSINUS (503), they provide insight into general eligibility criteria for allergy-related studies. Typical requirements include:
- Age between 18 and 65 years
- Diagnosis of moderate-to-severe allergic rhinitis or rhinoconjunctivitis for at least two years
- Positive skin prick test and specific IgE levels for the allergen being studied
- No history of serious reactions to immunotherapy
- No severe or uncontrolled asthma
- No significant immune system disorders or other severe health conditions
It's important to note that these criteria may vary for studies specifically focused on house dust mite allergies.
Safety Considerations
As with any medical treatment, there are several safety considerations to keep in mind:
- Allergic Reactions: Even though this substance is used to diagnose allergies, it can potentially cause allergic reactions in sensitive individuals.
- Proper Administration: The medication should only be administered by trained healthcare professionals in a controlled setting.
- Contraindications: Patients with certain health conditions, such as severe asthma or immune disorders, may not be suitable candidates for skin prick tests or immunotherapy treatments.
- Pregnancy and Breastfeeding: The safety of this substance during pregnancy or breastfeeding is not established in the provided information.
Always consult with a healthcare professional before undergoing any allergy tests or treatments.